BCM
CLDX icon

Bourgeon Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Bourgeon Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3
Closed -$134 – 338
2022
Q4 		$134 Hold
3
– – ﹤0.01% 362
2022
Q3 		$0 Hold
3
– – ﹤0.01% 381
2022
Q2 		$0 Hold
3
– – ﹤0.01% 289
2022
Q1 		$0 Hold
3
– – ﹤0.01% 287
2021
Q4 		$0 Hold
3
– – ﹤0.01% 267
2021
Q3 		$0 Hold
3
– – ﹤0.01% 277
2021
Q2 		$0 Hold
3
– – ﹤0.01% 277
2021
Q1 		$0 Hold
3
– – ﹤0.01% 278
2020
Q4 		$0 Hold
3
– – ﹤0.01% 274
2020
Q3 		$0 Hold
3
– – ﹤0.01% 300
2020
Q2 		$0 Buy
+3
New +$13 ﹤0.01% 258

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bourgeon Capital Management's CLDX Position: Q1 2023 in Review

Bourgeon Capital Management sold out of Celldex Therapeutics (CLDX) in Q1 2023, closing a stake of 3 shares — an estimated $134 sold.

Bourgeon Capital Management first reported a position in CLDX in Q2 2020 and held it in 11 quarters. The position peaked at $134 in Q4 2022. 161 funds tracked by Wall St. Rank hold CLDX as of Q1 2023.

  • Bourgeon Capital Management reported no remaining Celldex Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Bourgeon Capital Management sold 3 Celldex Therapeutics shares in Q1 2023, an estimated $134.
  • Bourgeon Capital Management first reported a position in Celldex Therapeutics in Q2 2020 and held it in 11 quarters.
  • Bourgeon Capital Management's Celldex Therapeutics position peaked at $134 in Q4 2022.
  • 161 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2023.

Based on Bourgeon Capital Management's 13F filing for Q1 2023, filed 17 Apr 2023.